PharmTech AI Pulse Check panelists explain why attribution, audit trails, and sign-off matter more than AI watermark detection for GxP quality teams.
News|Articles|April 30, 2020
UK Biotech Discovers Two Novel Treatments for COVID-19 Patients
Author(s)Pharmaceutical Technology Editors
ILC Therapeutics, a biotech company based in the United Kingdom, has discovered two separate novel treatments for patients suffering with COVID-19 prior to needing ventilators.
Advertisement
According to an April 30, 2020 press release, ILC Therapeutics, a biotech company based in the United Kingdom, has discovered two separate novel treatments for patients suffering with COVID-19 prior to needing ventilators.
The company has patented a new Interferon-Alpha subtype, Interferon Alpha 14, that can be administered via injection or inhalation and has the potential to prevent COVID-19 induced acute respiratory distress syndrome (ARDS). Additionally, in collaboration with Professor Shoumo Bhattacharya at the University of Oxford, the company is developing therapeutic Evasins-molecules derived from ticks-that have the potential to end an immune overreaction damaging the lungs (cytokine storm) in patients, even if the condition has advanced.
“There has been much talk within the scientific community of Interferon Alpha 2, but this is not an effective treatment method and frankly has stalled further interferon research by decades,” said Dr. Alan Walker, newly appointed CEO of ILC Therapeutics, in the press release. “ILCT’s Interferon Alpha 14 could prevent the need for patients to be put on ventilators by boosting their innate immune systems as the virus progresses. We have seen that few patients survive once they are put on ventilators, so the quicker we can develop this treatment in a safe and scalable way, the better.”
Bhattacharya, professor of Cardiovascular Medicine and BHF Chair at the University of Oxford, added, in the press release, “Evasins have proven pre-clinical efficacy against chemokines, which are important components of cytokine storms, and I am excited that their potential for managing COVID-19 cytokine storms will be studied.”
ILC Therapeutics is now seeking funding to accelerate safety studies and clinical trials of these two potential COVID-19 treatments.
Source:
Advertisement
Related to this article
Ron Scarboro, Azurity Pharmaceuticals, explains how cross-functional development, disciplined reformulation, and post-approval metrics can help proven medicines work in everyday use.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Richard Jaenisch examines whether FDA's NAM pathway truly shortens drug pipelines or just shifts the evidentiary burden elsewhere.
Susan J. Schniepp, distinguished fellow with Nelson Labs, and Siegfried Schmitt, PhD, vice president, Technical, with Parexel, clear up some of the confusion about what does and does not need to be complied with regarding standards set by international pharmacopoeias.
Advertisement
Advertisement